 | • レポートコード：MRC-IM31177 • 出版社/出版日：IMARC / 2023年3月 • レポート形態：英文、PDF、143ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥359,856 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥647,856 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| IMARC社の本調査レポートでは、2022年に20.4億ドルであった世界のデュシェンヌ型筋ジストロフィー治療薬市場規模が、2028年までに40億ドルに拡大し、予測期間中にCAGR11.41%で成長すると予想しています。本書は、デュシェンヌ型筋ジストロフィー治療薬の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、製品別（コルチコステロイド、疼痛管理薬）分析、治療アプローチ別（突然変異抑制、エクソンスキッピング療法、ステロイド療法）分析、エンドユーザー別（病院、診療所、在宅医療）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、要因・制約・機会、バリューチェーン分析、ポーターズファイブフォース分析、価格分析、競争状況などの項目を整理しています。また、本書には、FibroGen Inc.、Italfarmaco S.p.A.、NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)、PTC Therapeutics Inc.、Santhera Pharmaceuticals、Sarepta Therapeutics Inc.などの企業情報が含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界のデュシェンヌ型筋ジストロフィー治療薬市場規模：製品別 - コルチコステロイドの市場規模 - 疼痛管理薬の市場規模 ・世界のデュシェンヌ型筋ジストロフィー治療薬市場規模：治療アプローチ別 - 突然変異抑制における市場規模 - エクソンスキッピング療法における市場規模 - ステロイド療法における市場規模 ・世界のデュシェンヌ型筋ジストロフィー治療薬市場規模：エンドユーザー別 - 病院における市場規模 - 診療所における市場規模 - 在宅医療における市場規模 ・世界のデュシェンヌ型筋ジストロフィー治療薬市場規模：地域別 - 北米のデュシェンヌ型筋ジストロフィー治療薬市場規模 - アジアのデュシェンヌ型筋ジストロフィー治療薬市場規模 - 欧州のデュシェンヌ型筋ジストロフィー治療薬市場規模 - 中南米のデュシェンヌ型筋ジストロフィー治療薬市場規模 - 中東・アフリカのデュシェンヌ型筋ジストロフィー治療薬市場規模 ・要因・制約・機会 ・バリューチェーン分析 ・ポーターズファイブフォース分析 ・価格分析 ・競争状況 |
Market Overview:
The global Duchenne muscular dystrophy drugs market size reached US$ 2.04 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.00 Billion by 2028, exhibiting a growth rate (CAGR) of 11.41% during 2023-2028. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.
Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.
Duchenne Muscular Dystrophy Drugs Market Trends:
The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on product type, therapeutic approach, and end user.
Product Type Insights:
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Pain Management Drugs
The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.
Therapeutic Approach Insights:
Mutation Suppression
Exon Skipping
Steroid Therapy
The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.
End User Insights:
Hospitals
Clinics
Home Care Settings
A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global Duchenne muscular dystrophy drugs market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global Duchenne muscular dystrophy drugs market?
What are the key regional markets?
Which countries represent the most attractive Duchenne muscular dystrophy drugs markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the therapeutic approach?
What is the breakup of the market based on end user?
What is the competitive structure of the global Duchenne muscular dystrophy drugs market?
Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Duchenne Muscular Dystrophy Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Corticosteroids
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Prednisolone
6.1.2.2 Prednisone
6.1.2.3 Deflazacort
6.1.3 Market Forecast
6.2 Pain Management Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Therapeutic Approach
7.1 Mutation Suppression
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Exon Skipping
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Steroid Therapy
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Home Care Settings
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 FibroGen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Italfarmaco S.p.A.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 PTC Therapeutics Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Santhera Pharmaceuticals
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Sarepta Therapeutics Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and ChallengesFigure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2022
Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2022
Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2022
Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2022
Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2022
Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis
• 日本語訳：デュシェンヌ型筋ジストロフィー治療薬の世界市場：動向・シェア・規模・予測
• レポートコード：MRC-IM31177 ▷ お問い合わせ（見積依頼・ご注文・質問）